Advanced Search

 

Study ID Status Title Patient Level Data
208115 Not yet recruiting Meta-analysis to further assess the efficacy of mepolizumab 100mg SC on selected endpoints and to further investigate the relationship between efficacy endpoints, blood eosinophils and other important subgroups
208116 Not yet recruiting Meta-analysis to further assess the efficacy of mepolizumab 100mg subcutaneous dose on selected endpoints in subjects eligible for omalizumab treatment and other related subgroups
208127/132 (EXT Y2) Completed Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose Study Listed on ClinicalStudyDataRequest.com
208129/002 Completed Study to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals' (previously SmithKline Beecham Biologicals') MPL-adjuvanted recombinant hepatitis B vaccine versus Engerix™-B, in haemodialysis patients
208129/004 Completed Study to evaluate the immunogenicity and reactogenicity of GSK Biologicals' MPL-adjuvanted recombinant hepatitis B vaccine in comparison with those of Engerix™-B in healthy adult volunteers following 2 different schedules
208129/005 Completed Study to evaluate the immunogenicity and reactogenicity of various formulations of GSK Biologicals’ (previously SmithKline Beecham Biologicals') recombinant hepatitis B vaccine with different adjuvants in healthy adult volunteers
208129/006 Completed Study to evaluate the immunogenicity and reactogenicity of various formulations of GSK Biologicals' (previously SmithKline Beecham Biologicals') recombinant hepatitis B vaccine in healthy adult volunteers
208129/009 Completed Study to compare the immunogenicity, safety and reactogenicity of GSK Biologicals’ (previously SmithKline Beecham Biologicals') recombinant hepatitis B vaccines with and without adjuvant in healthy older adult volunteers
208129/016 Completed Study to compare the safety, immunogenicity and reactogenicity of different formulations of GSK Biologicals' (previously SmithKline Beecham Biologicals') MPL-adjuvanted recombinant hepatitis B vaccine to that of Engerix™-B
208129/019 Completed Study to assess the safety, immunogenicity and reactogenicity of GSK Biologicals' (previously SmithKline Beecham Biologicals') adjuvanted recombinant hepatitis B vaccine, recombinant hepatitis B vaccine new formulation and Engerix™-B
208129/021 Completed Study to compare the immunogenicity and reactogenicity of GSK Biologicals' (previously SmithKline Beecham Biologicals') MPL-adjuvanted recombinant hepatitis B vaccine with that of Engerix™-B in an adult non-responder population
208129/022 Completed Study comparing immunogenicity, reactogenicity and safety of GSK Biologicals' HBV-MPL vaccine with that of Engerix™-B when both are injected according to 3 dose schedule (0, 1, 6 months) in an adult population aged between 50 and 70 years
208129/025 Completed Study comparing the immunogenicity and reactogenicity of different formulations of GSK Biologicals' HBV-MPL vaccine injected as a 0, 6 months schedule with that of Engerix™-B injected as a 0, 1, 6 months schedule in healthy adults aged 18-40 years
208129/026 Completed Study comparing the immunogenicity and reactogenicity of different formulations of GSK Biologicals' HBV-MPL vaccine injected as a 0, 6 months schedule with that of Engerix™-B injected as a 0, 1, 6 months schedule in healthy adults aged 19-40 years
208129/027 Completed Study comparing the immunogenicity and reactogenicity of GSK Biologicals' HBV-MPL vaccine injected according to a 0, 6 months schedule with that of Engerix™-B injected as a 0, 1, 6 months schedule in a healthy adult population (15-40 years)
208129/028 Completed Study to assess the feasibility of GSK Biologicals' candidate HBV / MPL vaccines following different schedules and formulations and to compare their safety and immunogenicity to that of Engerix™-B in healthy adolescents aged 11 to 15 years
208129/030 Completed Study to evaluate the immunogenicity and safety of GSK Biologicals’ novel adjuvanted hepatitis B vaccine administered according to a 0, 6 month schedule and of Engerix™-B administered according to a 0, 1, 6 month schedule in healthy adults
208129/031 Completed Safety and immunogenicity of 3 lots of GSK Biologicals’ novel adjuvanted hepatitis B vaccine, administered according to a 2 dose schedule, and Engerix™-B administered according to a 3 dose schedule to healthy volunteers 15 years of age or older
208129/032 Completed A phase III, clinical trial comparing the immunogenicity and safety of SmithKline Beecham Biologicals new adjuvanted hepatitis B vaccine to a double dose of Engerix™-B, in pre-haemodialysis/haemodialysis patients (>=15 years of age) Study Listed on ClinicalStudyDataRequest.com
208129/033 Completed A study to compare the immunogenicity and safety of GSK Biologicals adjuvanted HBV vaccine to Engerix™-B, in a non-responder population ≥ 15 years of age, when administered intramuscularly, according to a 0, 1, 2, 12 month schedule
208129/034 Completed Phase III study to compare immunogenicity, safety and reactogenicity of GSK Biologicals’ novel adjuvanted hepatitis B vaccine adminstered intramuscularly, according to a 0, 6 month schedule, to Engerix™-B 20 mcg administered according to a 0,1,6 month schedule in healthy volunteers positive for the HLA-DQ2 genotype
208129/036 Completed Study to compare the immunogenicity and safety of GSK Biologicals’ novel adjuvanted HBV vaccine (0, 21-day schedule) to a double dose of Engerix™ -B (0, 7, 21-day schedule), in pre-liver transplant patients ≥ 18 y, boosted at month 6-12
208129/037 Completed Evaluating the consistency of 3 consecutive lots of GSK Biologicals' novel adjuvanted HBV vaccine with single-blind safety evaluation using Engerix™-B as a control, administered according to a 0, 1, 2-month schedule in healthy volunteers (15-50y).
208129/042 Completed To compare the immunogenicity and safety of GSK Biologicals' new adjuvanted hepatitis B vaccine to a double dose of Engerix™-B, in pre-haemodialysis/haemodialysis patients (15 years of age or older)
208129/047 Completed A phase III, clinical trial comparing the persistence of GSK Biologicals new adjuvanted hepatitis B vaccine to a double dose of Engerix™-B at months 24, 30, 36, in pre-haemodialysis/haemodialysis patients (≥15 years of age)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.